Funding round brings in $15M for Epitomics spinoff

05/23/2013 | MedCityNews.com

Apexigen, which specializes in developing new cancer drugs using rabbit-derived, humanized monoclonal antibodies, secured $15 million in an equity round. APX005, the California-based firm's lead drug candidate, is under development as a treatment for pancreatic cancer and other difficult-to-treat cancers.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY